Evidence map›Paper›PMID 38617212›Full record

ArticlebioRxiv : the preprint server for biology2024

Beyond Normalization: Incorporating Scale Uncertainty in Microbiome and Gene Expression Analysis.

Michelle Pistner Nixon, Gregory B Gloor, Justin D Silverman

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Michelle Pistner NixonCollege of Information Science and Technology, Pennsylvania State University, University Park, PA, USA.
Gregory B GloorDepartment of Biochemistry, The University of Western Ontario, London, ON, CAN.ORCID 0000-0001-5803-3380
Justin D SilvermanCollege of Information Science and Technology, Pennsylvania State University, University Park, PA, USA.ORCID 0000-0002-3063-2098

Funding

DMS/NIGMS 1: Addressing Measurement Limitations for Sequence Count DataR01GM148972 · NIGMS · PENNSYLVANIA STATE UNIVERSITY, THE · PI SILVERMAN, JUSTIN D · 2022 to 2024
$600k
NIGMS NIH HHS R01 GM148972
6 · The paper itself

Abstract

Though statistical normalizations are often used in differential abundance or differential expression analysis to address sample-to-sample variation in sequencing depth, we offer a better alternative. These normalizations often make strong, implicit assumptions about the scale of biological systems (e.g., microbial load). Thus, analyses are susceptible to even slight errors in these assumptions, leading to elevated rates of false positives and false negatives. We introduce scale models as a generalization of normalizations so researchers can model potential errors in assumptions about scale. By incorporating scale models into the popular ALDEx2 software, we enhance the reproducibility of analyses while often drastically decreasing false positive and false negative rates. We design scale models that are guaranteed to reduce false positives compared to equivalent normalizations. At least in the context of ALDEx2, we recommend using scale models over normalizations in all practical situations.

Identifiers

PMID38617212
PMCPMC11014594

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.